The Financial Impact of Antivascular Endothelial Growth Factor Drug Durability

Emily C. Davis, Tom Murickan, Ifrah Khurram, Sean T. Berkowitz, Charles Williard, Akshay S. Thomas

Open source

DOI
10.1177/24741264261498875
Published
2026-11-06
Container
Journal of VitreoRetinal Diseases
Publisher
SAGE Publications
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1177/24741264261498875,
  title = {The Financial Impact of Antivascular Endothelial Growth Factor Drug Durability},
  author = {Emily C. Davis and Tom Murickan and Ifrah Khurram and Sean T. Berkowitz and Charles Williard and Akshay S. Thomas},
  year = {2026},
  journal = {Journal of VitreoRetinal Diseases},
  doi = {10.1177/24741264261498875},
  url = {https://doi.org/10.1177/24741264261498875}
}

RIS

TY  - JOUR
TI  - The Financial Impact of Antivascular Endothelial Growth Factor Drug Durability
AU  - Emily C. Davis
AU  - Tom Murickan
AU  - Ifrah Khurram
AU  - Sean T. Berkowitz
AU  - Charles Williard
AU  - Akshay S. Thomas
PY  - 2026
JO  - Journal of VitreoRetinal Diseases
DO  - 10.1177/24741264261498875
UR  - https://doi.org/10.1177/24741264261498875
ER  - 

APA

Davis, E. C., Murickan, T., Khurram, I., Berkowitz, S. T., Williard, C., & Thomas, A. S. (2026). The Financial Impact of Antivascular Endothelial Growth Factor Drug Durability. Journal of VitreoRetinal Diseases. https://doi.org/10.1177/24741264261498875

Source records